Filtered shower heads may improve scalp and hair health but do not affect male pattern baldness (MPB). Genetics and factors like DHT and scalp tension are more significant in hair loss.
The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.
The individual is experiencing hair loss and has a vitamin D deficiency, with levels at 7.49ng/ml or 26nmol/l. They are unsure if the deficiency is causing the hair loss and are seeking advice on vitamin D supplementation.
The user is using topical minoxidil twice daily for hair regrowth and is hesitant to use finasteride due to concerns about hormonal effects. The conversation includes mixed opinions on the effectiveness of the treatment and suggestions to use a DHT blocker for better results.
The conversation discusses struggles with diffuse thinning and hair loss treatments, including the use of dutasteride, minoxidil, and finasteride, with limited success. The original poster regrets having a hair transplant at 21 due to weak donor hair and ongoing thinning.
The conclusion of the conversation is that dying the hair can be an effective method for managing hair loss, particularly for those with diffuse thinning.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
A user shared their 6-month progress with hair loss treatment, showing significant improvement. They used 1mg Propecia daily, Rogaine foam (5% minoxidil) after morning showers, and CG210 spray before bedtime.
A user shared their positive experience with a 2200 graft FUE hair transplant at DiStefano Hair Restoration in Worcester, MA, praising Dr. Heinis and his staff for their care. The user is also using oral Dutasteride, topical Minoxidil, and vitamins D and B.
People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.
A user decided to use a hair system after 10 years of hair loss, avoiding surgery and supplements due to potential side effects. They were nervous but hopeful for natural-looking results.
The user is experiencing significant hair thinning on the front scalp while taking oral finasteride and minoxidil. They are unsure if it's androgenetic alopecia or related to seborrheic dermatitis.
Dutasteride can cause hair shedding even with suppressed testosterone levels due to previous damage from DHT. Hair shedding is often a sign of damaged hair being replaced by healthier growth.
The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.
A child accidentally took Avodart, leading to concerns about DHT suppression and its effects. Users humorously discuss potential consequences and treatments like DHT injections and topical solutions.
People on testosterone replacement therapy (TRT) with aggressive androgenetic alopecia (AGA) discuss using Dutasteride or Finasteride, sometimes combined with topical treatments like RU58841 or CB-03-01 (Breezula), to prevent hair loss. Concerns about side effects and costs of certain treatments are mentioned, with one individual sharing their experience of slowed hair loss using Finasteride alone.
The user is using a regimen of 0.5mg dutasteride, 5% minoxidil foam at night, hair gummies, and rosemary water in the morning to address hair loss. They are experiencing some regrowth and are advised to be patient, with suggestions to possibly increase minoxidil application to twice a day for better results.
Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.
L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.
People are sharing their experiences of keeping a hidden folder on their phones with photos documenting their hair loss. Some users discuss the emotional impact, while one mentions using dutasteride and oral minoxidil without noticeable change.
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
The user is experiencing hair thinning and has a vitamin D deficiency, which they suspect might be causing the issue, but they are also considering androgenic alopecia (AGA) as a cause. They are currently using minoxidil and are unable to get finasteride prescribed, while others suggest addressing the vitamin D deficiency and consulting a dermatologist.
The conversation humorously discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It highlights a funny brand name found on Amazon related to derma stamps.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.